Search

Next Generation Cancer Diagnostics Market: Innovation-Driven Growth and Future Opportunities According to a newly published market research report by 24LifeSciences, global next generation cancer diagnostics market was valued at USD 8,060 million in 2026 and is projected to reach USD 28,120 million by 2034, growing at a compound annual growth rate (CAGR) of 20.0% during the forecast period. Next generation cancer diagnostics represent a paradigm shift from traditional histopathology. These advanced technologies enable highly sensitive and specific analysis of cancer biomarkers from various biological samples, with key platforms including Next Generation Sequencing (NGS), qPCR & Multiplexing, and DNA Microarrays. These tools are fundamental for applications such as early detection, companion diagnostics, treatment selection, and minimal residual disease monitoring, enabling a more precise and personalized approach to oncology. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8895/next-generation-cancer-diagnostics-market

Global Rapid Diagnostics Market Expands as Point-of-Care Testing Becomes Central to Healthcare Global rapid diagnostics market is witnessing robust expansion as healthcare systems worldwide prioritize early detection, faster clinical decisions, and decentralized testing models. Valued at approximately USD 46.7 billion in 2024, the market is projected to grow from USD 50.1 billion in 2025 to around USD 76.4 billion by 2032, registering a CAGR of 6.2% during the forecast period. This growth reflects the increasing reliance on rapid diagnostic solutions across hospitals, clinics, and community settings to improve patient outcomes and optimize healthcare efficiency. Access the complete report https://www.24lifesciences.com/rapid-diagnostics-market-9182

What Is the Future of the Prostate Cancer Diagnostics Market? Growth Forecasts & Insights Global prostate cancer diagnostics market is entering a phase of accelerated expansion, driven by rising cancer prevalence, improved screening awareness, and rapid advances in diagnostic technologies. Valued at USD 14.24 billion in 2024, the market is projected to grow from USD 15.43 billion in 2025 to USD 24.78 billion by 2031, registering a strong CAGR of 8.4% during the forecast period. This growth reflects a global shift toward early detection, risk-adapted screening, and precision diagnostics that support better clinical decision-making and patient outcomes. Read the full market study https://www.24lifesciences.com/prostate-cancer-diagnostics-market-6949